


## **Supplementary Materials**



Supplementary Figure 1: Flowchart of patient selection.




Supplementary Figure 2: The Kaplan–Meier curves for PB patients aged ≤5 years. (A) OS for the whole cohort, (B) OS stratified by age at diagnosis, (C) OS stratified by sex, (D) OS stratified by race, (E) OS stratified by tumor size, (F) OS stratified by metastasis status, (G) OS stratified by surgery procedure, (H) OS stratified by receipt of radiotherapy, (I) OS stratified by receipt of chemotherapy. OS: Overall survival; PB: Pineoblastoma.



Supplementary Figure 3: The Kaplan–Meier curves for PB patients aged ≤ 5 years.

(A) DSS for the whole cohort, (B) DSS stratified by age at diagnosis, (C) DSS stratified by sex, (D) DSS stratified by race, (E) DSS stratified by tumor size, (F) DSS stratified by metastasis status, (G) DSS stratified by surgery procedure, (H) DSS stratified by receipt of radiotherapy, (I) DSS stratified by receipt of chemotherapy.

DSS: Disease-specific survival; PB: Pineoblastoma.



**Supplementary Figure 4:** The developed nomograms to make individualized predictions of 1-year, 3-year, and 5-year (A) OS and (B) DSS. The calibration curves of the nomograms for 1-year, 3-year, and 5-year (C) OS and (D) DSS. DSS: Disease-specific survival; OS: Overall survival.

Supplementary Table 1: Baseline characteristics of PB patients aged ≤5 years in the SEER 18 Registry database, 1975–2016.

Characteristics	Number of patients	Percentage (%)		
Total	78	100		
Follow-up time (mont	th)			
Median (IQR)	18.00 (8.75 - 76.25)			
Age (years)				
Mean $\pm$ SD	$2.45 \pm 1.584$			
Median (IQR)	3.00 (1.00 - 3.25)			
< 1	11	14.1		
1	13	16.7		
2	14	17.9		
3	21	26.9		
4	8	10.3		
5	11	14.1		
Sex				
Male	41	52.6		
Female	37	47.4		
Race				
White	53	67.9		
Black	18	23.1		
Other	7	9.0		
Tumor size				
< 30 mm	16	20.5		
≥ 30 mm	19	24.4		
Unknown	43	55.1		
Metastasis				
No	29	37.2		
Yes	12	15.4		
Unknown	37	47.4		
Surgical procedure				
No surgery	9	11.5		
STR	14	17.9		
GTR	24	30.8		
Surgery, NOS	31	39.7		
Radiotherapy				
No	42	53.8		
Yes	36	46.2		
Chemotherapy				
No	13	16.7		
Yes	65	83.3		

PB: Pineoblastoma; SEER: Surveillance Epidemiology and End Results; STR: Subtotal resection; GTR: Gross-total resection; NOS: Not otherwise specified.

Supplementary Table 2: Univariate Cox proportional-hazard models for OS and DSS.

	Overall survival		Disease-specific survival		
Variable	HR (95% CI)	P	HR (95% CI)	P	
Age (years)		0.002		< 0.001	
< 1	Reference		Reference		
1	0.876 (0.336-2.283)	0.787	0.443 (0.161-1.219)	0.115	
2	0.293 (0.115-0.751)	0.011	0.132 (0.047-0.373)	< 0.001	
3	0.238 (0.097-0.585)	0.002	0.092 (0.032-0.263)	< 0.001	
4	0.169 (0.045-0.633)	0.008	0.084 (0.021-0.335)	< 0.001	
5	0.211 (0.074-0.603)	0.004	0.105 (0.034-0.322)	< 0.001	
Sex					
Male	Reference		Reference		
Female	0.860 (0.482-1.535)	0.610	0.846 (0.458-1.564)	0.594	
Race		0.788		0.725	
White	Reference		Reference		
Black	1.133 (0.581-2.207)	0.715	1.254 (0.632-2.487)	0.518	
Other	0.730 (0.223-2.393)	0.603	0.808 (0.244-2.676)	0.808	
<b>Tumor size</b>		0.822		0.812	
< 30 mm	Reference		Reference		
≥ 30 mm	0.768 (0.326-1.811)	0.547	0.825 (0.327-2.080)	0.683	
Unknown	0.928 (0.456-1.887)	0.836	1.063 (0.491-2.299)	0.877	
Metastasis		0.611		0.407	
No	Reference		Reference		
Yes	0.990 (0.406-2.409)	0.982	0.793 (0.287-2.187)	0.654	
Unknown	1.337 (0.705-2.534)	0.374	1.402 (0.721-2.724) 0.31		
Surgical		0.943	0.892		
procedure					
No surgery	Reference		Reference		
STR	1.357 (0.443-4.157)	0.593	1.116 (0.299-4.167)	0.870	
GTR	1.127 (0.409-3.103)	0.818	1.428 (0.473-4.308)	0.527	
Surgery, NOS	1.259 (0.467-3.395)	0.649	1.414 (0.475-4.209)	0.533	
Radiotherapy					
No	Reference		Reference		
Yes	0.321 (0.170-0.608)	< 0.00	0.301 (0.154-0.587)	< 0.001	
		1			
Chemotherapy					
No	Reference		Reference		
Yes	0.412 (0.203-0.835)	0.014	0.369 (0.180-0.758)	0.007	

HR, hazard ratio; CI, confidence interval; STR, subtotal resection; GTR, gross-total resection; NOS, not otherwise specified; DSS: Disease-specific survival; OS: Overall survival.